Article Text

Download PDFPDF

Aripiprazole is effective for relapse prevention in people with chronic stable schizophrenia

Statistics from

OpenUrlCrossRefPubMedWeb of Science

Q Does maintenance aripiprazole prevent relapse in people with chronic schizophrenia with residual symptomatology?


Embedded ImageDesign:

Randomised controlled trial.

Embedded ImageAllocation:


Embedded ImageBlinding:

Double blinded.

Embedded ImageFollow up period:

26 weeks; participants monitored daily.

Embedded ImageSetting:

31 centres in the USA, Czech Republic, Poland, Russia, and Ukraine; 2000–01.

Embedded ImagePatients:

310 adults with confirmed schizophrenia (DSM-IV) of at least 2 years’ duration with residual symptomatology despite antipsychotic treatment. Main inclusion criteria: ongoing antipsychotic treatment to which they had shown some response; Positive and Negative Syndrome Scale (PANSS) score of ⩾60 with score ⩽4 on the hostility or uncooperativeness subscales; Clinical Global Impressions-Severity of Illness scale (CGI-S) score ⩽4. Exclusions: acute relapse; psychiatric …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.